These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 23851632

  • 1. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
    Iacono P, Parodi MB, Introini U, La Spina C, Varano M, Bandello F.
    Retina; 2014 Feb; 34(2):281-7. PubMed ID: 23851632
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
    Kim JH, Chang YS, Kim JW, Kim CG, Yoo SJ, Cho HJ.
    Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
    Papavasileiou E, Steel DH, Liazos E, McHugh D, Jackson TL.
    Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
    Cho HJ, Koh KM, Kim JH, Kim HS, Han JI, Lew YJ, Lee TG, Kim JW.
    Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
    Parodi MB, Iacono P, Papayannis A, Kontadakis SD, Cascavilla M, Pierro L, Gagliardi M, Bandello F.
    Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
    Parodi MB, Iacono P, La Spina C, Iuliano L, Lo Giudice G, Introini U, Bandello F.
    Retina; 2014 Nov; 34(11):2167-70. PubMed ID: 24999724
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
    Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH.
    Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M, Iida T, Kano M.
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [Abstract] [Full Text] [Related]

  • 9. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [Abstract] [Full Text] [Related]

  • 10. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration.
    Lazzeri S, Figus M, Sartini MS, Scarinci F, Casini G, Guidi G, Cupo G, Cacciamani A, Fasanella V, Agnifili L, Piaggi P, Varano M, Ripandelli G, Nardi M, Parravano M.
    Ophthalmologica; 2015 May; 233(2):74-81. PubMed ID: 25662794
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U.
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 14. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y, Shimada H, Mori R, Tanaka K, Yuzawa M.
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 19. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Mar; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 20. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.